The Sputnik V COVID-19 vaccine by Russia is declared 92% accurate against the virus. This statement was released by the vaccine developer on Wednesday, after the Western competitor, Pfizer announced that its vaccine is 90% accurate.
These vaccine results are made on the results that were collected from 16,000 people which were given both doses of Russia’s Sputnik V COVID-19 vaccine. The Gamaleya research center along with the Russian Direct Investment Fund (RDIF) has made this statement with 92% accuracy, both of these agencies are runs under the Russian government.
The accuracy rate of the Sputnik V COVID-19 vaccine was recorded as 92% after the second dose was given to the volunteers. Nearly 20 of these participants were tested positive for the virus, as they received the placebo during this vaccine trial.
This Russian version of the COVID-19 vaccine used an already existing vector-based vaccine incorporated with the genetically modified strains of the regular influenza virus. Some of the people who were subjected to this vaccine reported mild pain at the site of the injection. Some of them also reported flu-like symptoms including headache, fever, weakness, and body pain.
Russia is the first country that came up with a coronavirus vaccine back in August, making it the first every country which registered a COVID-19 vaccine. However, its trials are still not completed.
Nearly 40,000 volunteers are a part of the final trial of Russia’s Sputnik V COVID-19 vaccine. They are being studied through 29 different medical centers in Russia.
Two months ago, this Russian vaccine was given to the medics who were the most exposed to coronavirus along with other high-risk groups of people who were working at the hospitals in Russia. Based on the results, this vaccine turned out to be 90% accurate.
Only a few of these medics contracted the virus, according to the regional health authorities. This statement released on Wednesday also says that the interim results of this research will be made public soon. They are all set to be published in the top-ranked and peer-reviewed medical journals.
This observational trial will last for six more months, after which the complete report on the trials will be published, the announcement said. It also shared that RDIF will provide the data on this Sputnik V research to other countries who are interested in knowing about this Russian vaccine or planning to purchase it.
Many overseas trials of this vaccine are also being held they added. This announcement of making the interim results of Sputnik V’s public is made within a few days after the Western pharmaceuticals Pfizer as well as BioNTech made an announcement related to their COVID-19 vaccines, calling them 90% accurate.